file1
,
file2
, etc. all in the same folder or directory;
first, locate one of the files with the [Browse...] button. Then alter the
file path in the box above to include '*' character (eg. file*
).
Wildcard '?' to blanket only one character works too.Historiographs |
Grand Totals: LCS 17722, GCS 106366, CR 136943 Collection span: 1963 - 2012 | |
Word(i) List (4568) Word count: 24159, All words count: 34321 |
# | Word | Recs | TLCS | TGCS |
---|---|---|---|---|
401 | OUTCOMES | 11 | 47 | 383 |
402 | PARENCHYMAL | 5 | 47 | 163 |
403 | PROGENITOR | 6 | 47 | 678 |
404 | PROLIFERATION | 17 | 47 | 560 |
405 | RECONSTITUTION | 5 | 47 | 77 |
406 | SYNTHESIS | 16 | 47 | 626 |
407 | ASPECTS | 27 | 46 | 348 |
408 | IRRADIATED | 5 | 46 | 74 |
409 | LIVER-TRANSPLANTS | 4 | 46 | 236 |
410 | MAJOR | 14 | 46 | 404 |
411 | REGIMEN | 7 | 46 | 192 |
412 | SHORT-TERM | 7 | 46 | 153 |
413 | TRANSPLANTATIONS | 6 | 46 | 352 |
414 | Y-CHROMOSOME | 6 | 46 | 174 |
415 | ADJUNCT | 4 | 45 | 70 |
416 | AMPLIFICATION | 8 | 45 | 100 |
417 | ANTISERUM | 4 | 45 | 159 |
418 | RESPONSIBLE | 5 | 45 | 434 |
419 | SEVERE | 11 | 45 | 266 |
420 | STATE | 6 | 45 | 133 |
421 | STEROID | 14 | 45 | 392 |
422 | SYNDROME | 14 | 45 | 357 |
423 | THYMUS | 17 | 45 | 419 |
424 | ADVERSE-EFFECTS | 1 | 44 | 168 |
425 | ANTI-LYMPHOBLAST | 4 | 44 | 188 |
426 | PRIMATES | 12 | 44 | 251 |
427 | RABBIT | 17 | 44 | 307 |
428 | SUPRALETHALLY | 1 | 44 | 65 |
429 | TOTAL | 5 | 44 | 785 |
430 | INFECTIOUS | 8 | 43 | 575 |
# | Word | Recs | TLCS | TGCS |
431 | LIVER-DERIVED | 2 | 43 | 164 |
432 | PATHWAYS | 5 | 43 | 678 |
433 | THYMECTOMY | 6 | 43 | 216 |
434 | VISCERA | 1 | 43 | 197 |
435 | ALLOANTIGEN-SPECIFIC | 2 | 42 | 240 |
436 | ANTITHYMOCYTE | 22 | 42 | 331 |
437 | DIAGNOSIS | 12 | 42 | 291 |
438 | ENZYMES | 3 | 42 | 416 |
439 | FACTOR-STIMULATED | 1 | 42 | 142 |
440 | HUMANS | 9 | 42 | 279 |
441 | HYPERPLASIA | 6 | 42 | 378 |
442 | MARROW-AUGMENTED | 3 | 42 | 63 |
443 | POSSIBLE | 11 | 42 | 309 |
444 | REQUIRED | 5 | 42 | 158 |
445 | ROLES | 2 | 42 | 87 |
446 | TESTING | 6 | 42 | 156 |
447 | AXONAL | 3 | 41 | 340 |
448 | B7-1 | 1 | 41 | 202 |
449 | B7-2 | 1 | 41 | 202 |
450 | CLINICOPATHOLOGICAL | 3 | 41 | 108 |
451 | CORRELATION | 8 | 41 | 260 |
452 | DEPLETION | 6 | 41 | 209 |
453 | FUTURE | 32 | 41 | 523 |
454 | GRAFT-SURVIVAL | 7 | 41 | 423 |
455 | NLDC | 1 | 41 | 202 |
456 | PROGNOSIS | 6 | 41 | 155 |
457 | TOLERANCE-ASSOCIATED | 1 | 41 | 102 |
458 | VISCERAL | 2 | 41 | 239 |
459 | VIVO | 10 | 41 | 332 |
460 | ADULTS | 6 | 40 | 158 |
# | Word | Recs | TLCS | TGCS |
461 | APPLICATION | 13 | 40 | 327 |
462 | CD80 | 1 | 40 | 243 |
463 | COSTIMULATORY | 3 | 40 | 247 |
464 | DOSAGES | 4 | 40 | 166 |
465 | ESTABLISHMENT | 6 | 40 | 83 |
466 | HOMING | 2 | 40 | 405 |
467 | MOLECULE-DEFICIENT | 1 | 40 | 243 |
468 | NONIMMUNOSUPPRESSED | 1 | 40 | 243 |
469 | SIDE-EFFECTS | 4 | 40 | 192 |
470 | UREMIA | 4 | 40 | 571 |
471 | ANTIGEN-SPECIFIC | 4 | 39 | 380 |
472 | COMPARATIVE | 10 | 39 | 380 |
473 | DEATH | 11 | 39 | 466 |
474 | DETECTED | 2 | 39 | 85 |
475 | PARADIGMS | 2 | 39 | 58 |
476 | PATTERNS | 11 | 39 | 191 |
477 | PLASMA-LEVELS | 2 | 39 | 110 |
478 | POTENT | 8 | 39 | 236 |
479 | RESISTANCE | 5 | 39 | 294 |
480 | CD8 | 9 | 38 | 444 |
481 | CUTANEOUS | 12 | 38 | 687 |
482 | DRUG | 22 | 38 | 813 |
483 | GLOMERULONEPHRITIS | 8 | 38 | 263 |
484 | IMPROVES | 5 | 38 | 169 |
485 | BILIARY | 7 | 37 | 401 |
486 | FLT3 | 5 | 37 | 193 |
487 | FORMED | 3 | 37 | 591 |
488 | INVITRO | 18 | 37 | 419 |
489 | RECONSTRUCTION | 5 | 37 | 231 |
490 | STEROID-RESISTANT | 6 | 37 | 161 |
# | Word | Recs | TLCS | TGCS |
491 | TOXICITY | 11 | 37 | 443 |
492 | 2-WAY | 1 | 36 | 54 |
493 | BOWEL | 31 | 36 | 237 |
494 | CULTURED | 6 | 36 | 181 |
495 | CYCLOPHOSPHAMIDE | 6 | 36 | 164 |
496 | HOMOTRANSPLANTED | 2 | 36 | 168 |
497 | MILESTONES | 2 | 36 | 57 |
498 | ONE-WAY | 1 | 36 | 54 |
499 | PRESENT | 14 | 36 | 366 |
500 | SPECIFIC | 13 | 36 | 301 |
501 | VIEWED | 1 | 36 | 54 |
502 | ALTERS | 3 | 35 | 148 |
503 | COMBINING | 5 | 35 | 98 |
504 | DIABETES-MELLITUS | 9 | 35 | 392 |
505 | EVENTS | 5 | 35 | 178 |
506 | LIMB | 14 | 35 | 104 |
507 | PROTEIN | 16 | 35 | 818 |
508 | ACHIEVEMENT | 3 | 34 | 74 |
509 | AUGMENTS | 5 | 34 | 124 |
510 | CLAMPING | 1 | 34 | 86 |
511 | CONTROLLED | 6 | 34 | 136 |
512 | CONVALESCENCE | 1 | 34 | 65 |
513 | EXPERIMENTS | 2 | 34 | 147 |
514 | FETAL | 8 | 34 | 809 |
515 | HEPATIC-DYSFUNCTION | 1 | 34 | 86 |
516 | KIDNEYS | 17 | 34 | 235 |
517 | LEARNED | 7 | 34 | 461 |
518 | LYMPHOCYTES-T | 2 | 34 | 582 |
519 | PCR-FLOW | 1 | 34 | 69 |
520 | PROGRESS | 11 | 34 | 239 |
# | Word | Recs | TLCS | TGCS |
521 | SUSTAINED | 2 | 34 | 115 |
522 | T-TUBE | 1 | 34 | 86 |
523 | TEST | 3 | 34 | 144 |
524 | TRANSMISSION | 4 | 34 | 1061 |
525 | ANTIDONOR | 3 | 33 | 82 |
526 | CAUSES | 8 | 33 | 308 |
527 | CENTER | 7 | 33 | 418 |
528 | DUCT | 7 | 33 | 229 |
529 | HPLC | 3 | 33 | 193 |
530 | IMMUNOSUPPRESSANTS | 11 | 33 | 317 |
531 | LESSONS | 9 | 33 | 405 |
532 | LYMPHATIC | 5 | 33 | 113 |
533 | MALIGNANCY | 2 | 33 | 255 |
534 | ONSET | 4 | 33 | 174 |
535 | PERIOPERATIVE | 7 | 33 | 164 |
536 | POSTOPERATIVE | 7 | 33 | 150 |
537 | PROTECTS | 4 | 33 | 166 |
538 | PURIFICATION | 3 | 33 | 112 |
539 | SEQUENTIAL | 9 | 33 | 239 |
540 | ACTIVATION-ASSOCIATED | 1 | 32 | 65 |
541 | ADRENOCORTICAL | 1 | 32 | 51 |
542 | ASSOCIATION | 8 | 32 | 136 |
543 | BABOON-TO-HUMAN | 1 | 32 | 296 |
544 | DISTINCT | 3 | 32 | 672 |
545 | DONOR-RECIPIENT | 5 | 32 | 96 |
546 | HIGH | 9 | 32 | 369 |
547 | HIGH-DOSE | 4 | 32 | 82 |
548 | HOMOTRANSPLANTATIONS | 1 | 32 | 112 |
549 | INTRAGRAFT | 7 | 32 | 123 |
550 | REGULATORY | 14 | 32 | 224 |
# | Word | Recs | TLCS | TGCS |
551 | RELATIONSHIP | 8 | 32 | 109 |
552 | REPLACEMENT | 10 | 32 | 450 |
553 | REVERSING | 1 | 32 | 51 |
554 | SMALL | 33 | 32 | 2486 |
555 | SPLIT | 6 | 32 | 138 |
556 | ABO | 7 | 31 | 237 |
557 | ARTERIOPATHY | 2 | 31 | 173 |
558 | COMPLETE | 6 | 31 | 272 |
559 | CONSIDERATIONS | 13 | 31 | 291 |
560 | CYTOMETRY | 2 | 31 | 52 |
561 | KEY | 1 | 31 | 138 |
562 | ANTI-SERUM | 1 | 30 | 81 |
563 | ASSAY | 8 | 30 | 160 |
564 | CASE | 14 | 30 | 205 |
565 | CLEAR | 1 | 30 | 74 |
566 | COMPLEXES | 3 | 30 | 1035 |
567 | DEPENDS | 1 | 30 | 89 |
568 | DRUG-FREE | 1 | 30 | 52 |
569 | FREQUENT | 1 | 30 | 52 |
570 | INHIBITED | 1 | 30 | 552 |
571 | LEADING | 3 | 30 | 262 |
572 | LYMPHOBLASTS | 2 | 30 | 82 |
573 | NESTED | 4 | 30 | 58 |
574 | PERSIST | 2 | 30 | 593 |
575 | PHARMACOLOGY | 5 | 30 | 288 |
576 | PROSPECTS | 15 | 30 | 180 |
577 | QUANTITY | 1 | 30 | 89 |
578 | REGULATORS | 3 | 30 | 293 |
579 | RENAL-HOMOGRAFT | 2 | 30 | 412 |
580 | SECONDARY | 8 | 30 | 161 |
# | Word | Recs | TLCS | TGCS |
581 | SHORT-COURSE | 3 | 30 | 76 |
582 | ALLOSTIMULATORY | 3 | 29 | 101 |
583 | ANTIHUMAN | 7 | 29 | 173 |
584 | CHIMPANZEES | 2 | 29 | 113 |
585 | CLINICAL-EXPERIENCE | 4 | 29 | 191 |
586 | CONCEPT | 3 | 29 | 68 |
587 | CONTINUED | 3 | 29 | 113 |
588 | GLOMERULAR | 9 | 29 | 324 |
589 | IMMUNOLOGY | 18 | 29 | 186 |
590 | INTERLEUKIN-2 | 6 | 29 | 105 |
591 | ISLETS | 8 | 29 | 189 |
592 | LANGERHANS | 9 | 29 | 267 |
593 | LITERATURE | 9 | 29 | 200 |
594 | LOWER | 3 | 29 | 117 |
595 | METABOLITE | 3 | 29 | 160 |
596 | ORGANS | 9 | 29 | 116 |
597 | POSTPARTUM | 1 | 29 | 585 |
598 | RECOVERY | 7 | 29 | 220 |
599 | SELECTION | 7 | 29 | 68 |
600 | STRATEGIES | 20 | 29 | 368 |